Rainbow Children's Medicare Ltd - 543524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the Regulation 30 of the SEBI Listing Regulations, please find attached copies of newspaper advertisement of Financial Results of the Company for the quarter ended on June 30, 2022, published in Financial Express and Surya on August 9, 2022. Rainbow Children's Medicare Ltd - 543524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find herewith a revised earnings presentation on unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2022. The presentation shared earlier carried an error on slide 17 (titled: Restated consolidated statement of profit and loss), where the title headings for periods have been interchanged. The same has been rectified in copy attached herewith. Q1FY23 Quarterly Result Announced for Rainbow Childrens Medicare Ltd.
Rainbow Childrens Medicare announced Q1FY23 results: The revenues for Q1FY23 stood at Rs.2371.52 million, when compared to Rs. 2,463.57 million in Q1FY22 The operating EBIDTA for Q1FY23 was Rs. 820.91 million, which is a growth of 5% compared to Rs. 782.64 million in Q1FY22 PAT for Q1FY23 was Rs. 387.61 million, which is a growth of 8% compared to Rs. 358.80 million in Q1FY22. Commenting on the performance for Q1 FY2023 Dr. Ramesh Kancharla, Chairman & Managing Director, Rainbow Children’s Medicare Limited (RCML) said, “We have witnessed business normalising to pre-COVID levels with all the operating parameters demonstrating healthy growth compared to previous quarters, with schools having reopened across the country and children returning to near normal life. We expect healthy growth across our pediatric super specialty services as we are witnessing strong demand for these services across the hospitals. The OMR, Chennai spoke hospital is expected to commence operations in the current quarter and all other projects under execution are progressing well and are expected to commence operations within the stated timelines. The revenues for Q1FY23 stood at Rs. 2371.52 million, when compared to Rs. 2,463.57 million in Q1FY22. However, adjusting for the COVID vaccine revenue of 440 mn in Q1FY22, the revenue for Q1FY23 has grown at 17% compared to the revenue in Q1FY22. The operating EBIDTA for Q1FY23 was Rs. 820.91 million, which is a growth of 5% compared to Rs. 782.64 million in Q1FY22 and the PAT for Q1FY23 was Rs. 387.61 million, which is a growth of 8% compared to Rs. 358.80 million in Q1FY22. With focus on pediatric super-specialties and quaternary care, we are building a powerful ecosystem backed by neonatal and pediatric intensive care services. As our network of hospitals expands we shall be in a better position to serve a larger patient pool, addressing the strong underlying requirement for children focused quality hospitals in the country.” Result PDF Rainbow Children's Medicare Ltd - 543524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2022. Rainbow Children's Medicare Ltd - 543524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached herewith Earnings Presentation of the Company on Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2022, which the Company proposes to share with analysts/investors. We request you to kindly take the same on record. Rainbow Children's Medicare Ltd - 543524 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
The Board of Directors of Rainbow Children's Medicare Limited ('the Company') in their meeting held today i.e. August 8, 2022, has approved the Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM. The details of the reclassification of Authorised Share Capital is described below: 'Reclassification of Authorized Share Capital from INR. 150,00,00,000 divided into (a) 13,90,55,616 Equity Shares of INR 10/- each (b) 11,46,771 - Series A 0.0001% Compulsorily Convertible Preference Shares ('Series A CCPS') of INR. 48/- each and (c) 11,33,309 Series B 0.0001% Compulsorily Convertible Preference Shares ('Series B CCPS') of INR. 48/- to INR. 150,00,00,000 divided into 15,00,00,000 Equity Shares of INR 10/- each.' Rainbow Children's Medicare Ltd - 543524 - Convening Of 24Th Annual General Meeting ('AGM') Of The Company On Thursday September 15, 2022.
Convening of 24th Annual General Meeting ('AGM') of the Company on Thursday September 15, 2022 at 11:30 AM through Video Conferencing/ Other Audio Visual Means (VC/OVAM). Rainbow Children's Medicare Ltd - 543524 - The Board Has Fixed September 8, 2022 As The Record Date For The Purpose Of Payment Of Final Dividend.
Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders at the ensuing AGM). Rainbow Children's Medicare Ltd - 543524 - Board Meeting Outcome for 1. Unaudited Financial Results For The First Quarter Ended June 30, 2022. 2. Convening Of 24Th AGM On Thursday September 15, 2022 3. Fixation Of Record Date For The Purpose Of Payment Of Final Dividend For Financial Year 2021-22 As September 8, 2022
1. The unaudited Standalone and Consolidated Financial Results ("Results") of the Company for the first Quarter ended June 30, 2022. Copies of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith. 2. Convening of 24th Annual General Meeting ('AGM') of the Company on Thursday September 15, 2022 through Video Conferencing/ Other Audio Visual Means (VC/OVAM). 3. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021-22 (if approved by the Shareholders at the ensuing AGM). 4. Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM. Rainbow Children's Medicare Ltd - 543524 - The Unaudited Standalone And Consolidated Financial Results ("Results") Of The Company For The First Quarter Ended June 30, 2022.
1. The unaudited Standalone and Consolidated Financial Results ("Results") of the Company for the first Quarter ended June 30, 2022. Copies of the signed Results along with Limited Review Reports issued by the Statutory Auditors M/s. BSR & Associates LLP are attached herewith. 2. Convening of 24th Annual General Meeting ("AGM") of the Company on Thursday, September 15, 2022 through Video Conferencing/ Other Audio Visual Means (VC/OVAM). 3. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed September 8, 2022 as the Record Date for the purpose of payment of Final Dividend for Financial Year 2021- 22 (if approved by the Shareholders at the ensuing AGM). 4. Reclassification of Authorised Share Capital of the Company and consequently, amend the capital clause of the Memorandum of Association, subject to approval of the members of the Company in the ensuing AGM.